Table 2.
Braak ROI staging based on AV-1451 uptake.
| Stage 0 | Stage I/II | Stage III/IV | Stage V/VI | |
|---|---|---|---|---|
| SUVR thresholds (PVC) | BraakI/II ROI ≤1.129 | BraakI/II ROI > 1.129 | BraakIII/IV ROI > 1.304 | BraakV/VI ROI > 1.873 |
| Original Sample (BACS/UCSF) | ||||
| n (YC/OC-Aβ-/OC-Aβ+/AD) ntotal = 5/18/15/15 | 3/1/3/0 | 2/15/8/0 | 0/2/4/1 | 0/0/0/14 |
| New Sample (BACS/UCSF) | ||||
| n (MAC/OC-Aβ-/OC-Aβ+/MCI/AD) ntotal = 7/23/18/12/33 | 4/9/1/0/0 | 3/13/11/3/1 | 0/1/6/5/3 | 0/0/0/4/29 |
| Original+New (BACS/UCSF) | ||||
| n (YC+MAC/OC-Aβ-/OC-Aβ+/MCI/AD) ntotal =12/41/33/12/48 | 7/10/4/0/0 | 5/28/19/3/1 | 0/3/10/5/4 | 0/0/0/4/43 |
| New Sample (ADNI) | ||||
| n (OC-Aβ-/OC-Aβ+/MCI/AD) ntotal = 28/14/19/9 | 7/2/3/0 | 20/5/5/3 | 1/7/10/5 | 0/0/1/1 |
| Total (BACS/UCSF+ADNI) | ||||
| n (YC+MAC/OC-Aβ-/OC-Aβ+/MCI/AD) ntotal = 12/69/47/31/57 | 7/17/6/3/0 | 5/48/24/8/4 | 0/4/17/15/9 | 0/0/0/5/44 |
| Percentage of group within stage (YC+MAC/OC-Aβ-/OC-Aβ+/MCI/AD) | 58/25/13/10/0 | 42/70/51/26/7 | 0/6/36/48/16 | 0/0/0/16/77 |
Number of participants within a specific in vivo “Braak” stage. An initial subgroup of BACS/UCSF subjects (“original sample”) was used to derive Braak ROI thresholds using a regression-based conditional interference tree approach. Thresholds were tested on a new subgroup of BACS/UCSF subjects as well as on ADNI participants. See also Supplementary Fig. S2. YC=young controls (age range 20-26 yrs), MAC=middle-aged